Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Sarcopenia is an age-related clinical complaint characterized by the progressive deterioration of skeletal muscle mass and strength over time. Type 2 diabetes (T2D) is associated with faster and more relevant skeletal muscle impairment. Both conditions influence each other, leading to negative consequences on glycemic control, cardiovascular risk, general health status, risk of falls, frailty, overall quality of life, and mortality. PubMed/Medline, Scopus, Web of Science, and Google Scholar were searched for research articles, scientific reports, observational studies, clinical trials, narrative and systematic reviews, and meta-analyses to review the evidence on the pathophysiology of di-abetes-induced sarcopenia, its relevance in terms of glucose control and diabetes-related outcomes, and diagnostic and therapeutic challenges. The review comprehensively addresses key elements for the clinical definition and diagnostic criteria of sarcopenia, the pathophysiological correlation be-tween T2D, sarcopenia, and related outcomes, a critical review of the role of antihyperglycemic treatment on skeletal muscle health, and perspectives on the role of specific treatment targeting myokine signaling pathways involved in glucose control and the regulation of skeletal muscle metabolism and trophism. Prompt diagnosis and adequate management, including lifestyle inter-vention, health diet programs, micronutrient supplementation, physical exercise, and pharmaco-logical treatment, are needed to prevent or delay skeletal muscle deterioration in T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“[207].”
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Janssen, I., Heymsfield, S. B., & Ross, R. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50216.x · Cited by 3,139 · cited 1×
“Sarcopenia is defined when individual skeletal muscle index is lower than one standard deviation compared to reference values [3].”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“The leading therapeutic effects of GLP-1RAs include the enhancement of glucose-dependent insulin release and suppression of glucagon secretion during hyperglycemia, but not hypoglycemia, delay of gastric emptying, and sup-Nutrients pression of appetite [175,176].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Muscle–Organ Crosstalk: The Emerging Roles of Myokines
Severinsen, M. C. K., & Pedersen, B. K. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa016 · Cited by 1,226 · cited 1×
“Preserving skeletal muscle endocrine functions means maintaining essential crosstalk between skeletal muscle and several tissues, such as the brain, adipose tissue, bones, the liver, gut microbiome, pancreatic islets, microvasculature, skin, and muscle itself [226].”
BackgroundAge-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102 · cited 2×
“Insulin resistance, hyperglycemia, and T2D per se induce mitochondrial dysfunction, impaired oxidative metabolism, and energetic utilization, contributing to sarcopenia [12].”
BackgroundBody Composition in Healthy Aging
BAUMGARTNER, R. N. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06498.x · Cited by 1,078 · cited 2×
“According to the New Mexico Aging Process Study [29], sarcopenic obesity is diagnosed when skeletal muscle mass is at least two standard deviations below the mean reference value for weight-normalized skeletal muscle mass, i.e., 7.26 kg/m 2 in men and 5.45 kg/m 2 in women, and body fat mass is…”
MethodInfluentialTyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Mechanisms of muscle atrophy and hypertrophy: implications in health and disease
Sartori, R., Romanello, V., & Sandri, M. (2021) · Nature Communications · doi:10.1038/s41467-020-20123-1 · Cited by 940 · cited 1×
“Myostatin, transforming growth factor β , activins, and growth differentiation factor are the foremost negative regulators [41,42].”
BackgroundThe Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It
The Look AHEAD Research Group (2006) · Obesity · doi:10.1038/oby.2006.84 · Cited by 873
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851 · cited 1×
“Metformin, a biguanide approved for T2D, is widely used as a first-line treatment of T2D [106].”
BackgroundSrikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake
Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442 · cited 1×
“%) after a 12-week intensive lifestyle intervention [209].”
BackgroundCan physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity?
Duggal, N. A., Niemiro, G., Harridge, S. D. R., Simpson, R. J., & Lord, J. M. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0177-9 · Cited by 436
Dietary Advanced Glycation End Products and Aging
Luevano-Contreras, C., & Chapman-Novakofski, K. (2010) · Nutrients · doi:10.3390/nu2121247 · Cited by 396
Hong, S.-H., & Choi, K. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020494 · Cited by 390
Effect of Estrogen on Musculoskeletal Performance and Injury Risk
Chidi-Ogbolu, N., & Baar, K. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01834 · Cited by 389
Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise
Corcoran, M. P., Lamon-Fava, S., & Fielding, R. A. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.3.662 · Cited by 341 · cited 2×
“Resident macrophages are known to induce and sustain inflammation in the adipose tissue, pancreatic islets, liver, and other peripheral tissues [10], with a significant contribution to the pathophysiology of T2D.”
BackgroundFrias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01163-7 · Cited by 334 · cited 1×
“Slightly lower but significant results were also found in obese individuals with T2D, as demonstrated by the SURMOUNT-2 trial [208].”
ResultExercise interventions for the prevention and treatment of sarcopenia. A systematic umbrella review.
Beckwée, D., Delaere, A., Aelbrecht, S., Baert, V., Beaudart, C., Bruyere, O., de Saint-Hubert, M., & Bautmans, I. (2019) · The Journal of nutrition, health and aging · doi:10.1007/s12603-019-1196-8 · Cited by 330
Effect of Vitamin D Supplementation on Testosterone Levels in Men
Pilz, S., Frisch, S., Koertke, H., Kuhn, J., Dreier, J., Obermayer-Pietsch, B., Wehr, E., & Zittermann, A. (2011) · Hormone and Metabolic Research · doi:10.1055/s-0030-1269854 · Cited by 325
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316 · cited 1×
“Dual GLP-1/GIP co-agonists have recently been approved for T2D [195], and GLP-1/glucagon co-agonists and triple (glucagon, GLP-1, and GIP) agonists are under investigation [196,197].”
BackgroundAdipo-myokines: two sides of the same coin–mediators of inflammation and mediators of exercise
Raschke, S., & Eckel, J. (2013) · Mediators of Inflammation · doi:10.1155/2013/320724 · Cited by 296
Interleukin 6 as an Energy Allocator in Muscle Tissue
Kistner, T. M., Pedersen, B. K., & Lieberman, D. E. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00538-4 · Cited by 295
Buford, T. W., Anton, S. D., Judge, A. R., Marzetti, E., Wohlgemuth, S. E., Carter, C. S., Leeuwenburgh, C., Pahor, M., & Manini, T. M. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.004 · Cited by 295
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Regulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273 · cited 1×
“Physical exercise, directly or through indirect metabolic changes, such as low insulin-to-glucagon ratio, GH, and IGF1, enhances the synthesis of myokines and promotes the liver-mediated secretion of follistatin with a net effect on skeletal muscle gain [63,64].”
BackgroundGielen, E., Beckwée, D., Delaere, A., De Breucker, S., Vandewoude, M., Bautmans, I., the Sarcopenia Guidelines Development Group of the Belgian Society of Gerontology and Geriatrics (BSGG), Bautmans, I., Beaudart, C., Beckwée, D., et al. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuaa011 · Cited by 269
Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis
Feng, L., Gao, Q., Hu, K., Wu, M., Wang, Z., Chen, F., Mei, F., Zhao, L., & Ma, B. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab884 · Cited by 243 · cited 2×
“Poor glucose control, longer diabetes evolution, and the presence of chronic diabetes-related complications also increase the risk of sarcopenia in T2D [6–9].”
BackgroundVitamin D and male reproduction
Jensen, M. B. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.262 · Cited by 242 · cited 1×
“Vit-D receptors were found in testicular tissue, especially Leydig cells, where the vitamin is locally activated [95] and stimulates the synthesis of testosterone [96,97].”
BackgroundSargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice
Benoit, B., Meugnier, E., Castelli, M., Chanon, S., Vieille-Marchiset, A., Durand, C., Bendridi, N., Pesenti, S., Monternier, P.-A., Durieux, A.-C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4363 · Cited by 225
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1710 · Cited by 208
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202 · cited 1×
“Dual GLP-1/GIP co-agonists have recently been approved for T2D [195], and GLP-1/glucagon co-agonists and triple (glucagon, GLP-1, and GIP) agonists are under investigation [196,197].”
BackgroundCurrent and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195 · cited 1×
“Testosterone, estradiol, and GH and IGF1 provide essential anabolic stimuli to increase skeletal muscle mass and reverse skeletal muscle impairment [68].”
BackgroundSedentary behavior as a mediator of type 2 diabetes
Hamilton, M. T., Hamilton, D. G., & Zderic, T. W. (2014) · Medicine and Sport Science · doi:10.1159/000357332 · Cited by 185 · cited 1×
“Physical inactivity and a sedentary lifestyle are associated with insulin resistance, poor glucose control, and metabolically related consequences, including metabolic syndrome, T2D, obesity, and cardiovascular diseases [47,48].”
BackgroundAnti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182
PGC-1α modulates denervation-induced mitophagy in skeletal muscle
Vainshtein, A., Desjardins, E. M., Armani, A., Sandri, M., & Hood, D. A. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0033-y · Cited by 181
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
Smith, S. R., de Jonge, L., Volaufova, J., Li, Y., Xie, H., & Bray, G. A. (2005) · Metabolism · doi:10.1016/j.metabol.2004.07.008 · Cited by 176 · cited 1×
“Because of the adipogenic potential of thiazolidinediones, fat mass gain at the subcutaneous but not visceral adipose tissue site [153,154] is a common finding in T2D.”
BackgroundWu, P.-Y., Huang, K.-S., Chen, K.-M., Chou, C.-P., & Tu, Y.-K. (2021) · Maturitas · doi:10.1016/j.maturitas.2020.12.009 · Cited by 168
Gibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142 · cited 1×
“Targeting energy expenditure, fat oxidation, appetite regulation, and lean mass preservation are key elements for sustainable weight loss in metabolic disorders, including T2D [224].”
BackgroundMorvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig, M. H., Ahmad, K., Moon, J. S., Park, S.-Y., Ho Lim, J., Chun, H. J., Qadri, A. F., Hwang, Y. C., Jan, A. T., Ahmad, S. S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.876078 · Cited by 135 · cited 1×
“Suppressing the adenosine monophosphate-activate protein kinase (AMPK)–mammalian target of rapamycin (mTOR) pathway by the TGF-β -small mother against decapentaplegic (Smad) signaling results in impaired muscle synthesis and muscle atrophy [66,67].”
BackgroundSarma, S., & Palcu, P. (2022) · Obesity · doi:10.1002/oby.23563 · Cited by 133 · cited 1×
“Overall, the promising results of dual agonists are approaching those obtained with bariatric surgery [210,211], in a magnitude never seen until today [212].”
BackgroundQiao, Y.-S., Chai, Y.-H., Gong, H.-J., Zhuldyz, Z., Stehouwer, C. D. A., Zhou, J.-B., & Simó, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.782391 · Cited by 132 · cited 1×
“Poor glucose control, longer diabetes evolution, and the presence of chronic diabetes-related complications also increase the risk of sarcopenia in T2D [6–9].”
BackgroundCirculating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio
Hansen, J. S., Rutti, S., Arous, C., Clemmesen, J. O., Secher, N. H., Drescher, A., Gonelle-Gispert, C., Halban, P. A., Pedersen, B. K., Weigert, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3668 · Cited by 125
Bouchi, R., Nakano, Y., Fukuda, T., Takeuchi, T., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0449 · Cited by 113
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
SGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s425642 · Cited by 100
Safarpour, P., Daneshi-Maskooni, M., Vafa, M., Nourbakhsh, M., Janani, L., Maddah, M., Amiri, F.-S., Mohammadi, F., & Sadeghi, H. (2020) · BMC Family Practice · doi:10.1186/s12875-020-1096-3 · Cited by 100 · cited 1×
“Interestingly, Vit-D supplementation increases the level of circulating irisin by directly stimulating the intramuscular synthesis of its precursor (fibronectin type III domain-containing protein 5 or FNDC5) [234], which probably mediates both metabolic and functional parameters [235,236].”
BackgroundProtein intake and physical function in older adults: A systematic review and meta-analysis
Coelho-Júnior, H. J., Calvani, R., Tosato, M., Landi, F., Picca, A., & Marzetti, E. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101731 · Cited by 86
Tan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01321-5 · Cited by 83
Rosiglitazone modifies the adipogenic potential of human muscle satellite cells
De Coppi, P., Milan, G., Scarda, A., Boldrin, L., Centobene, C., Piccoli, M., Pozzobon, M., Pilon, C., Pagano, C., Gamba, P., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0304-6 · Cited by 81
Testicular Synthesis and Vitamin D Action
Hofer, D., Münzker, J., Schwetz, V., Ulbing, M., Hutz, K., Stiegler, P., Zigeuner, R., Pieber, T. R., Müller, H., & Obermayer-Pietsch, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1690 · Cited by 79
Takada, S., Masaki, Y., Kinugawa, S., Matsumoto, J., Furihata, T., Mizushima, W., Kadoguchi, T., Fukushima, A., Homma, T., Takahashi, M., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw182 · Cited by 78
Effects of Age and Sedentary Lifestyle on Skeletal Muscle NF- B Signaling in Men
Buford, T. W., Cooke, M. B., Manini, T. M., Leeuwenburgh, C., & Willoughby, D. S. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp196 · Cited by 78 · cited 1×
“A sedentary lifestyle is associated with loss of mechanical stimuli, consequent impairment of skeletal muscle trophism [49], skeletal muscle loss [50], and impaired myokine secretion.”
BackgroundVolpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73
Self-citationVolpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., et al. (2022) · Nutrients · doi:10.3390/nu14122414 · Cited by 67 · cited 1×
“Real-life studies have confirmed previous findings in T2D patients with and without weight excess up to one year of treatment [183–185].”
MethodSelf-citationVitamin D and Testosterone in Healthy Men: A Randomized Controlled Trial
Lerchbaum, E., Pilz, S., Trummer, C., Schwetz, V., Pachernegg, O., Heijboer, A. C., & Obermayer-Pietsch, B. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01428 · Cited by 60 · cited 1×
“Compared to standard supplementation of VIT-D (800–1000 IU/day), high-dose Vit-D (>3000 IU/day per 1 year) increases circulating levels of testosterone in healthy individuals [102,103].”
Backgroundde Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59
Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome
Warshauer, J. T., Lopez, X., Gordillo, R., Hicks, J., Holland, W. L., Anuwe, E., Blankfard, M. B., Scherer, P. E., & Lingvay, I. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2662 · Cited by 51 · cited 1×
“Moreover, thiazolidinediones reduce circulating and intramuscular levels of ceramides [150], which play a pathophysiological role in insulin resistance in skeletal muscle and accentuate the risk of age-related sarcopenia in T2D [151].”
BackgroundYabe, D., Kawamori, D., Seino, Y., Oura, T., & Takeuchi, M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14882 · Cited by 48 · cited 1×
“Despite remarkable weight loss, tirzepatide was found to selectively reduce fat, but not free-fat mass, as recently demonstrated [213,214].”
BackgroundHankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15269 · Cited by 44
Gut microbiota in common elderly diseases affecting activities of daily living
Shimizu, Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i42.4750 · Cited by 40
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
Guarnotta, V., Bianco, M. J., Vigneri, E., Panto’, F., Lo Sasso, B., Ciaccio, M., Pizzolanti, G., & Giordano, C. (2021) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.07.015 · Cited by 36
Deng, F., Wu, W., Fan, X., Zhong, X., Wang, N., Wang, Y., Pan, T., & Du, Y. (2023) · International Journal of Endocrinology · doi:10.1155/2023/9926462 · Cited by 26
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
Yamada, S., Ogura, Y., Inoue, K., Tanabe, J., Sugaya, T., Ohata, K., Nagai, Y., Natsuki, Y., Hoshino, S., Watanabe, S., et al. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111472 · Cited by 25 · cited 1×
“DPPIVis improve exercise tolerance in patients with heart failure by stimulating mitochondrial biogenesis in skeletal muscles [133,134].”
BackgroundHolt, R., Yahyavi, S. K., Kooij, I., Poulsen, N. N., Juul, A., Jørgensen, N., & Blomberg Jensen, M. (2024) · Andrology · doi:10.1111/andr.13505 · Cited by 21
Miazgowski, T., Kaczmarkiewicz, A., Miazgowski, B., & Kopeć, J. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01415-1 · Cited by 12
Cited by
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00027-0 · Cited by 131
Research progress on sarcopenia in the musculoskeletal system
Mao, X., Lv, K., Qi, W., Cheng, W., Li, T., Sun, Y., Jin, H., Pan, H., & Wang, D. (2025) · Bone Research · doi:10.1038/s41413-025-00455-8 · Cited by 37
“11,12 Notably, several pathogenic mechanisms contributing to sarcopenia share common features with degenerative musculoskeletal disorders, including chronic low-grade in fl ammation, mitochondrial dysfunction, ectopic fat deposition, and metabolic dysregulation.”
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Vozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1674308 · Cited by 12
Self-citation
Metadata
- Authors
- Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R., Guastamacchia, E., De Pergola, G., & Triggiani, V.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2023-12-25
- Volume
- 16
- Issue
- 1
- Pages
- 63
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W4390196775
- Cited by
- 101
- References
- 83
- FWCI
- 14.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.